Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 396
Filtrar
1.
BMC Cardiovasc Disord ; 21(1): 113, 2021 02 25.
Artículo en Inglés | MEDLINE | ID: mdl-33632131

RESUMEN

BACKGROUND: Obtaining vascular access can be challenging during resuscitation following cardiac arrest, and it is particularly difficult and time-consuming in paediatric patients. We aimed to compare the efficacy of high-dose intramuscular (IM) versus intravascular (IV) epinephrine administration with regard to the return of spontaneous circulation (ROSC) in an asphyxia-induced cardiac arrest rat model. METHODS: Forty-five male Sprague-Dawley rats were used for these experiments. Cardiac arrest was induced by asphyxia, and defined as a decline in mean arterial pressure (MAP) to 20 mmHg. After asphyxia-induced cardiac arrest, the rats were randomly allocated into one of 3 groups (control saline group, IV epinephrine group, and IM epinephrine group). After 540 s of cardiac arrest, cardiopulmonary resuscitation was performed, and IV saline (0.01 cc/kg), IV (0.01 mg/kg, 1:100,000) epinephrine or IM (0.05 mg/kg, 1:100,000) epinephrine was administered. ROSC was defined as the achievement of an MAP above 40 mmHg for more than 1 minute. Rates of ROSC, haemodynamics, and arterial blood gas analysis were serially observed. RESULTS: The ROSC rate (61.5%) of the IM epinephrine group was less than that in the IV epinephrine group (100%) but was higher than that of the control saline group (15.4%) (log-rank test). There were no differences in MAP between the two groups, but HR in the IM epinephrine group (beta coefficient = 1.02) decreased to a lesser extent than that in the IV epinephrine group with time. CONCLUSIONS: IM epinephrine induced better ROSC rates compared to the control saline group in asphyxia-induced cardiac arrest, but not compared to IV epinephrine. The IM route of epinephrine administration may be a promising option in an asphyxia-induced cardiac arrest.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Asfixia/complicaciones , Epinefrina/administración & dosificación , Paro Cardíaco/tratamiento farmacológico , Retorno de la Circulación Espontánea/efectos de los fármacos , Animales , Asfixia/fisiopatología , Modelos Animales de Enfermedad , Paro Cardíaco/etiología , Paro Cardíaco/fisiopatología , Hemodinámica/efectos de los fármacos , Inyecciones Intramusculares , Inyecciones Intravenosas , Masculino , Ratas Sprague-Dawley , Factores de Tiempo
2.
Anesth Analg ; 132(4): 1129-1137, 2021 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-33464760

RESUMEN

BACKGROUND: Bupivacaine and ropivacaine are the preferred long-acting local anesthetics for peripheral nerve blocks as they provide prolonged analgesia in the postoperative period. No studies have directly compared the analgesic duration of these commonly used local anesthetics in the setting of low-volume ultrasound-guided interscalene block (US-ISB). This study was designed to determine which local anesthetic and concentration provides superior analgesia (duration and quality) for low-volume US-ISB. METHODS: Sixty eligible patients scheduled for arthroscopic shoulder surgery were randomized (1:1:1) to receive US-ISB (5 mL) with 0.5% bupivacaine with 1:200,000 epinephrine, 0.5% ropivacaine, or 1% ropivacaine. All individuals were blinded including study participants, anesthesiologists, surgeons, research personnel, and statistician. All participants received a standardized general anesthetic and multimodal analgesia. The primary outcome was duration of analgesia defined as the time from the end of injection to the time that the patients reported a significant increase in pain (>3 numeric rating scale [NRS]) at the surgical site. RESULTS: The mean duration of analgesia for 0.5% bupivacaine with 1:200,000 epinephrine, 0.5% ropivacaine, or 1% ropivacaine was 14.1 ± 7.4, 13.8 ± 4.5, and 15.8 ± 6.3 hours, respectively (analysis of variance [ANOVA], P = .51). There were no observed differences in analgesic duration or other secondary outcomes between the 3 groups with the exception of a difference in cumulative opioid consumption up to 20h00 on the day of surgery in favor of ropivacaine 0.5% over bupivacaine of minimal clinical significance. CONCLUSIONS: In the context of single-injection low-volume US-ISB, we have demonstrated a similar efficacy between equal concentrations of ropivacaine and bupivacaine. In addition, increasing the concentration of ropivacaine from 0.5% to 1% did not prolong the duration of US-ISB.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Anestésicos Locales/administración & dosificación , Bloqueo del Plexo Braquial , Bupivacaína/administración & dosificación , Epinefrina/administración & dosificación , Dolor Postoperatorio/prevención & control , Ropivacaína/administración & dosificación , Ultrasonografía Intervencional , Agonistas Adrenérgicos/efectos adversos , Adulto , Anciano , Analgésicos Opioides/uso terapéutico , Anestésicos Locales/efectos adversos , Artroscopía/efectos adversos , Bloqueo del Plexo Braquial/efectos adversos , Bupivacaína/efectos adversos , Epinefrina/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Actividad Motora/efectos de los fármacos , Ontario , Dimensión del Dolor , Umbral del Dolor/efectos de los fármacos , Dolor Postoperatorio/diagnóstico , Dolor Postoperatorio/etiología , Dolor Postoperatorio/fisiopatología , Ropivacaína/efectos adversos , Articulación del Hombro/cirugía , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
3.
Exp Neurol ; 339: 113612, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33453213

RESUMEN

This paper is an interdisciplinary narrative review of efficacious non-invasive therapies that are increasingly used to restore function in people with chronic spinal cord injuries (SCI). First presented are the secondary injury cascade set in motion by the primary lesion and highlights in therapeutic development for mitigating the acute pathophysiologic process. Then summarized are current pharmacological strategies for modulation of noradrenergic, serotonergic, and dopaminergic neurotransmission to enhance recovery in bench and clinical studies of subacute and chronic SCI. Last examined is how neuromechanical devices (i.e., electrical stimulation, robotic assistance, brain-computer interface, and augmented sensory feedback) could be comprehensively engineered to engage efferent and afferent motosensory pathways to induce neuroplasticity-based neural pattern generation. Emerging evidence shows that computational models of the human neuromusculoskeletal system (i.e., human digital twins) can serve as functionalized anchors to integrate different neuromechanical and pharmacological interventions into a single multimodal prothesis. The system, if appropriately built, may cybernetically optimize treatment outcomes via coordination of heterogeneous biosensory, system output, and control signals. Overall, these rehabilitation protocols involved neuromodulation to evoke beneficial adaptive changes within spared supraspinal, intracord, and peripheral neuromuscular circuits to elicit neurological improvement. Therefore, qualitatively advancing the theoretical understanding of spinal cord neurobiology and neuromechanics is pivotal to designing new ways to reinstate locomotion after SCI. Future research efforts should concentrate on personalizing combination therapies consisting of pharmacological adjuncts, targeted neurobiological and neuromuscular repairs, and brain-computer interfaces, which follow multimodal neuromechanical principles.


Asunto(s)
Interfaces Cerebro-Computador , Terapia por Estimulación Eléctrica , Prótesis Neurales , Plasticidad Neuronal/fisiología , Recuperación de la Función/fisiología , Traumatismos de la Médula Espinal/terapia , Agonistas Adrenérgicos/administración & dosificación , Animales , Interfaces Cerebro-Computador/tendencias , Terapia Combinada/métodos , Terapia Combinada/tendencias , Terapia por Estimulación Eléctrica/métodos , Terapia por Estimulación Eléctrica/tendencias , Humanos , Prótesis Neurales/tendencias , Traumatismos de la Médula Espinal/diagnóstico , Traumatismos de la Médula Espinal/fisiopatología
4.
Tokai J Exp Clin Med ; 45(4): 195-201, 2020 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-33300590

RESUMEN

OBJECTIVE: Breath sound parameters have been reported as useful biomarkers for evaluating the airway condition. METHODS: The reliability of breath sound analysis using an improved method was investigated. Eighty-three asthmatic children were included in the present study. After adjusting the 0 level based on the background noises of the breath sound spectrum, the total area under the curve of the dBm (AT), the roll-off from 600-1200 Hz (Slope), the ratio of the third and fourth area to the AT (A3/AT and B4/AT), and the ratio of power and frequency at 50% and 75% of the highest frequency (RPF75 and RPF50), were evaluated before and after ß2 agonist inhalation. Spirography and the forced oscillation technique were also used to evaluate all subjects. RESULTS: Using the new method, A3/AT, B4/AT, RPF75 and RPF50, were significantly increased after ß2 agonist inhalation. The increase in A3/AT and B4/AT were significantly correlated with the increase in FEV1 and FEE25-75, and the increase in RPF75 was reversibly correlated with that in R5-R20. CONCLUSIONS: The spectrum curve indices using the adjusted 0 level can indicate bronchial dilation with ß2 agonist inhalation. These parameters may be useful for the assessment of bronchial reversibility in asthmatic children.


Asunto(s)
Asma/diagnóstico , Pruebas de Función Respiratoria/métodos , Ruidos Respiratorios , Administración por Inhalación , Adolescente , Agonistas Adrenérgicos/administración & dosificación , Asma/tratamiento farmacológico , Asma/patología , Bronquios/patología , Niño , Dilatación Patológica , Femenino , Humanos , Masculino , Reproducibilidad de los Resultados
5.
Eur J Pharmacol ; 889: 173619, 2020 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-33011242

RESUMEN

Neuropathic pain is a critical burdensome problem due to the complex interplay of several pathological mechanisms and lack of availability of effective therapeutic interventions. The available therapeutic options are associated with a variety of limitations, including severe side effects, and unmet medical needs, warranting further research to identify and validate potential targets. Adenosine receptors system is a widely studied target, which evidently was successful in alleviation of neuropathic pain in several experimental paradigms, and researchers are putting efforts in building its clinical roadmap. The adenosine receptors act by different mechanisms and targeting adenosine receptors for neuropathic pain includes several important pathways such as p38-mitogen-activated protein kinases (MAPK), extracellular signal-regulated kinases (ERK), brain-derived neurotrophic factor (BDNF) signalling, γ-aminobutyric acid (GABA) as well as the ion channel modulations. Various studies have also shown the relevance of targeting adenosine receptors in chemotherapy-induced neuropathic pain and diabetic neuropathy. Several drugs acting on adenosine receptors have undergone clinical trials for management of neuropathic pain, whereas many other drugs are yet to be studied to find a potential anti-nociceptive agent. In this review, we have discussed the roadmap of adenosine receptors as a potential target for the treatment of neuropathic pain.


Asunto(s)
Agonistas Adrenérgicos/metabolismo , Analgésicos/metabolismo , Neuralgia/metabolismo , Receptores Purinérgicos P1/metabolismo , Transducción de Señal/fisiología , Agonistas Adrenérgicos/administración & dosificación , Analgésicos/administración & dosificación , Animales , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Humanos , Neuralgia/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Ácido gamma-Aminobutírico/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
6.
BMC Cardiovasc Disord ; 20(1): 452, 2020 10 16.
Artículo en Inglés | MEDLINE | ID: mdl-33066731

RESUMEN

BACKGROUND: Epinephrine, in all modes of use, may pose a wide range of cardiotoxic events, ranging from sinus tachycardia to heart failure, life threatening arrhythmias, and even death. Because of daily and extensive use of epinephrine, these unusual and rare events tend to be forgotten by physicians. We present a case of dilated cardiomyopathy that developed following routine use of epinephrine-impregnated tampons during function endoscopic sinus (FESS) surgery. CASE PRESENTATION: A healthy, 24-year-old man with no family history of heart disease has undergone elective surgery under general anesthesia to repair the paranasal sinuses using endoscopic approach. During surgery, soon after being treated with 1: 1000 diluted epinephrine-soaked tampons, an hypertensive crisis was noticed followed by pulseless electrical activity. An extensive examination led to the diagnosis of non-ischemic dilated cardiomyopathy. After several days of heart failure medical therapy, complete resolution of all structural and functional changes was achieved. CONCLUSION: In our case, we present an unusual and rare event of acute dilated cardiomyopathy following the use of epinephrine-soaked tampons during elective FESS surgery. A prompt response was observed after several days of heart failure treatment. Awareness of the epinephrine cardiotoxic potential even in the form of soaked tampons is essential for proper diagnosis and prompt treatment.


Asunto(s)
Agonistas Adrenérgicos/efectos adversos , Cardiomiopatía Dilatada/inducido químicamente , Endoscopía , Epinefrina/efectos adversos , Procedimientos Quírurgicos Nasales , Senos Paranasales/cirugía , Enfermedad Aguda , Agonistas Adrenérgicos/administración & dosificación , Cardiomiopatía Dilatada/diagnóstico por imagen , Cardiomiopatía Dilatada/tratamiento farmacológico , Cardiotoxicidad , Epinefrina/administración & dosificación , Humanos , Masculino , Tampones Quirúrgicos , Resultado del Tratamiento , Adulto Joven
7.
Curr Opin Allergy Clin Immunol ; 20(5): 452-458, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32739981

RESUMEN

PURPOSE OF REVIEW: Epinephrine is the agreed-upon first line treatment for anaphylaxis, yet it continues to be underused by patients/caregivers and providers alike. RECENT FINDINGS: There are unfortunately limited data on how epinephrine can best be utilized in anaphylaxis, which hinders how best to inform patients and providers. Studies reporting underuse suggest various barriers and themes on why this may happen. SUMMARY: Continued education of patients, caregivers, and providers is needed; however, is not likely to be enough to close the gap. Thus, novel studies on how to increase use; increase availability in a cost-effective manner; and newer, effective delivery routes are still needed.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Anafilaxia/tratamiento farmacológico , Epinefrina/administración & dosificación , Adulto , Cuidados Posteriores/métodos , Animales , Niño , Modelos Animales de Enfermedad , Utilización de Medicamentos , Adhesión a Directriz , Humanos , Inyecciones Intramusculares , Resultado del Tratamiento
8.
Drug Dev Res ; 81(6): 716-727, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32359095

RESUMEN

Ocular allergy is one of the most common disorders of the eye surface. The conventional eye drops lack of therapeutic efficacy due to low ocular bioavailability and decreased drug residence time on eye surface. Hence, the present research work aimed to formulate, optimize, and evaluate the in situ gel for ophthalmic drug delivery. The prepared in situ gel formulations were evaluated for clarity, pH, gelling capacity, viscosity, osmolality, in vitro release study, and kinetic evaluation. ex vivo corneal permeation/penetration study using goat and in vivo studies on rabbits were also performed. Fourier-transformed infrared spectroscopy was also applied to study possible interactions between drug and polymers. The formulations found to be stable, nonirritant, and showed sustained release of the drug for a period of up to 24 hr with no ocular damage. The developed in situ gels loaded with tetrahydrozoline are alternative and promising ocular candidates for the treatment of allergic conjunctivitis.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Conjuntivitis Alérgica/tratamiento farmacológico , Imidazoles/administración & dosificación , Descongestionantes Nasales/administración & dosificación , Agonistas Adrenérgicos/química , Animales , Córnea/efectos de los fármacos , Córnea/metabolismo , Liberación de Fármacos , Geles , Imidazoles/química , Descongestionantes Nasales/química , Conejos
9.
J Am Heart Assoc ; 9(11): e014330, 2020 06 02.
Artículo en Inglés | MEDLINE | ID: mdl-32441184

RESUMEN

Background The use of adrenaline in out-of-hospital cardiac arrest (OHCA) patients is still controversial. This study aimed to determine the effects of early pre-hospital adrenaline administration in OHCA patients. Methods and Results PubMed, EMBASE, Google Scholar, and the Cochrane Library database were searched from study inception to February 2019 to identify studies that reported OHCA patients who received adrenaline. The primary outcome was survival to discharge, and the secondary outcomes were return of spontaneous circulation, favorable neurological outcome, and survival to hospital admission. A total of 574 392 patients were included from 24 studies. The use of early pre-hospital adrenaline administration in OHCA patients was associated with a significant increase in survival to discharge (risk ratio [RR], 1.62; 95% CI, 1.45-1.83; P<0.001) and return of spontaneous circulation (RR, 1.50; 95% CI, 1.36-1.67; P<0.001), as well as a favorable neurological outcome (RR, 2.09; 95% CI, 1.73-2.52; P<0.001). Patients with shockable rhythm cardiac arrest had a significantly higher rate of survival to discharge (RR, 5.86; 95% CI, 4.25-8.07; P<0.001) and more favorable neurological outcomes (RR, 5.10; 95% CI, 2.90-8.97; P<0.001) than non-shockable rhythm cardiac arrest patients. Conclusions Early pre-hospital administration of adrenaline to OHCA patients might increase the survival to discharge, return of spontaneous circulation, and favorable neurological outcomes. Registration URL: https://www.crd.york.ac.uk/PROSPERO; Unique identifier: CRD42019130542.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Servicios Médicos de Urgencia , Epinefrina/administración & dosificación , Paro Cardíaco Extrahospitalario/tratamiento farmacológico , Agonistas Adrenérgicos/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Epinefrina/efectos adversos , Femenino , Mortalidad Hospitalaria , Humanos , Masculino , Persona de Mediana Edad , Paro Cardíaco Extrahospitalario/diagnóstico , Paro Cardíaco Extrahospitalario/mortalidad , Paro Cardíaco Extrahospitalario/fisiopatología , Alta del Paciente , Retorno de la Circulación Espontánea/efectos de los fármacos , Factores de Tiempo , Resultado del Tratamiento
10.
Cardiovasc Drugs Ther ; 34(2): 189-197, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32146637

RESUMEN

PURPOSE: To compare intraosseous access with peripheral venous access on adults out-of-hospital cardiac arrest (OHCA) patients' clinical outcomes. METHODS: A national retrospective multicentre study was conducted based on the French National Cardiac Arrest Registry. Comparison of patients (intraosseous vs. peripheral venous access) was conducted before and after a matching using a propensity score. The propensity score included confounding factors: age, time between the call (T0) to epinephrine (to take account of how quickly vascular access was achieved), the aetiology of OHCA, the shock and the patient initial rhythm at MMT arrival. RESULTS: A total of 1576 patients received intraosseous access, and 27,280 received peripheral intravenous access. Before matching, OHCA patients with intraosseous access were less likely to survive at all stages (return of spontaneous circulation (ROSC), 0-day survival and 30-day survival). No significant difference in neurological outcome was observed. After propensity score matching, no significant differences in 30-day survival rates (OR = 0.763 [0.473;1.231]) and neurological outcome (OR = 1.296 [0.973;1.726]) were observed. However, intraosseous patients still showed lower likelihood of short-term survival (ROSC and 0-day survival) even after propensity score matching was implemented. CONCLUSION: The populations we investigated were similar to those of other studies suggesting that intraosseous access is associated with reduced survival and poorer neurological outcome. Our findings suggest that intraosseous access is a comparably effective alternative to peripheral intravenous access for treating OHCA patients on matched populations.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Cateterismo Periférico , Epinefrina/administración & dosificación , Paro Cardíaco Extrahospitalario/terapia , Resucitación/métodos , Administración Intravenosa , Anciano , Cateterismo Periférico/efectos adversos , Epinefrina/efectos adversos , Femenino , Francia , Humanos , Infusiones Intraóseas , Masculino , Paro Cardíaco Extrahospitalario/diagnóstico , Paro Cardíaco Extrahospitalario/mortalidad , Recuperación de la Función , Resucitación/efectos adversos , Resucitación/mortalidad , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
11.
Physiol Rep ; 8(3): e14370, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32061187

RESUMEN

The liver is the primary metabolic organ involved in the endogenous production of glucose through glycogenolysis and gluconeogenesis. Hepatic glucose production (HGP) is increased via neural-hormonal mechanisms such as increases in catecholamines. To date, the effects of prior exercise training on the hepatic response to epinephrine have not been fully elucidated. To examine the role of epinephrine signaling on indices of HGP in trained mice, male C57BL/6 mice were either subjected to 12 days of voluntary wheel running or remained sedentary. Epinephrine, or vehicle control, was injected intraperitoneally on day 12 prior to sacrifice with blood glucose being measured 15 min postinjection. Epinephrine caused a larger glucose response in sedentary mice and this was paralleled by a greater reduction in liver glycogen in sedentary compared to trained mice. There was a main effect of epinephrine to increase the phosphorylation of protein kinase-A (p-PKA) substrates in the liver, which was driven by increases in the sedentary, but not trained, mice. Similarly, epinephrine-induced increases in the mRNA expression of hepatic adrenergic receptors (Adra1/2a, Adrb1), and glucose-6-phosphatase (G6pc) were greater in sedentary compared to trained mice. The mRNA expression of cAMP-degrading enzymes phosphodiesterase 3B and 4B (Pde3b, Pde4b) was greater in trained compared to sedentary mice. Taken together, our data suggest that prior exercise training reduces the liver's response to epinephrine. This could be beneficial in the context of training-induced glycogen sparing during exercise.


Asunto(s)
Agonistas Adrenérgicos/farmacología , Epinefrina/farmacología , Hígado/metabolismo , Esfuerzo Físico , Agonistas Adrenérgicos/administración & dosificación , Animales , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Epinefrina/administración & dosificación , Gluconeogénesis , Glucosa-6-Fosfato/metabolismo , Glucógeno/metabolismo , Inyecciones Intravenosas , Hígado/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Hidrolasas Diéster Fosfóricas/metabolismo , Receptores Adrenérgicos/metabolismo
12.
J Glaucoma ; 29(3): 175-183, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31790066

RESUMEN

PRECIS: As new glaucoma treatments arise, including minimally invasive glaucoma surgeries and new classes of glaucoma medications, it is important to examine the prescription trends of current topical glaucoma medications and how they may change. PURPOSE: To determine the prescribing trends of topical glaucoma medications in Australia from 2001 to 2017. METHODS AND ANALYSIS: Pharmaceutical Benefits Scheme (PBS) item numbers were used to determine glaucoma medication prescribing rates from 2001 to 2017. All data were adjusted for population (/100,000) as per the Australian Bureau of Statistics (ABS) population data. RESULTS: Overall prescription rates for glaucoma medications ranged between 67,904 and 86,936 per 100,000 from 2001 to 2017. An upward trend was noted from 2001 to 2015, with the exception of a notable decline in 2013 by 14.7%, before then increasing by 13.7% in 2014. After 2015, prescribing rates were seen to decrease over the subsequent years in the study period. Latanoprost remained the most prescribed medication and prostaglandin the most prescribed class. Prescribing rates of single-agent beta-blockers were noted to decrease during the 17-year period, particularly with the introduction of combination agents, which note an upward trend. Brinzolamide/brimonidine has increased by 50.0% from 2016 to 2017. CONCLUSIONS: Total rates of prescriptions have remained relatively stable from 2001 to 2017. The number of medications prescribed when considering combination agents separately was seen to be increasing from 2001 to 2015. From 2015 to 2017, a downward trend was noted in the number of medications prescribed. Prostaglandins remain the most prescribed class throughout the study period.


Asunto(s)
Antihipertensivos/administración & dosificación , Prescripciones de Medicamentos/estadística & datos numéricos , Glaucoma de Ángulo Abierto/tratamiento farmacológico , Presión Intraocular/efectos de los fármacos , Pautas de la Práctica en Medicina/tendencias , Administración Oftálmica , Agonistas Adrenérgicos/administración & dosificación , Australia , Tartrato de Brimonidina/administración & dosificación , Inhibidores de Anhidrasa Carbónica/administración & dosificación , Quimioterapia Combinada , Utilización de Medicamentos/tendencias , Investigación sobre Servicios de Salud , Encuestas Epidemiológicas , Humanos , Soluciones Oftálmicas , Sulfonamidas/administración & dosificación , Tiazinas/administración & dosificación , Timolol/administración & dosificación
14.
Circ J ; 83(12): 2479-2486, 2019 11 25.
Artículo en Inglés | MEDLINE | ID: mdl-31645507

RESUMEN

BACKGROUND: This study examined the association between prehospital supraglottic airway (SGA) and/or epinephrine compared with bag-mask ventilation (BMV) and Glasgow-Pittsburgh cerebral performance category (CPC) 1 status in patients with out-of-hospital cardiac arrest (OHCA) using a large, nationwide, population-based registry dataset.Methods and Results:This was a post hoc analysis of the All-Japan Utstein Registry. We included patients with OHCA of cardiac origin aged ≥18 years with resuscitation performed by emergency medical services (EMS) between January 2011 and December 2015. The primary endpoint was favorable neurological outcome (CPC 1). The patients were divided into 4 groups according to the prehospital management performed by EMS: BMV group received only basic life support (BLS); epinephrine group received BLS plus epinephrine; SGA group received BLS plus SGA; and combined group received BLS plus epinephrine and SGA. Univariate and multivariable logistic regression analyses were performed for the primary endpoint. Among the 106,434 patients with OHCA, 48,847 received only BMV, 8,958 received BLS+epinephrine, 25,467 received BLS+SGA, and 15,551 received BLS+epinephrine+SGA. Using the BMV group as the reference, multivariable analysis showed that the epinephrine, SGA, and combined groups were independently associated with a reduced incidence of favorable neurological outcomes. CONCLUSIONS: Our results indicated that compared with BLS, patients in the prehospital SGA and/or epinephrine groups had a significantly reduced incidence of CPC 1 status.


Asunto(s)
Manejo de la Vía Aérea/instrumentación , Encéfalo/fisiopatología , Reanimación Cardiopulmonar/instrumentación , Servicios Médicos de Urgencia , Escala de Coma de Glasgow , Máscaras Laríngeas , Paro Cardíaco Extrahospitalario/terapia , Respiración Artificial/instrumentación , Agonistas Adrenérgicos/administración & dosificación , Anciano , Anciano de 80 o más Años , Manejo de la Vía Aérea/efectos adversos , Reanimación Cardiopulmonar/efectos adversos , Epinefrina/administración & dosificación , Diseño de Equipo , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Paro Cardíaco Extrahospitalario/diagnóstico , Paro Cardíaco Extrahospitalario/fisiopatología , Recuperación de la Función , Sistema de Registros , Respiración Artificial/efectos adversos , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
15.
Rev Alerg Mex ; 66 Suppl 2: 1-39, 2019.
Artículo en Español | MEDLINE | ID: mdl-31443138

RESUMEN

Anaphylaxis is a severe allergic reaction with a rapid onset and it is potentially life-threatening. Its clinical manifestations are varied; they may affect the skin, the cardiovascular system, the respiratory system, and the digestive system, among others. The treatment of choice, which is an intra-muscular injection of epinephrine (adrenaline), must be applied promptly. Therefore, being prepared to recognize it properly is of crucial importance. The objective of this clinical practice guide is to improve the knowledge of health professionals about anaphylaxis and, consequently, to optimize the treatment and long-term management of this reaction. This guide is adapted to the peculiarities of Latin America; especially in matters regarding the treatment. The need to introduce epinephrine auto-injectors in countries that don't have them yet is highlighted.


La anafilaxia es una reacción alérgica grave de instauración rápida y potencialmente mortal. Sus manifestaciones clínicas son muy variadas, pudiendo afectar la piel, el sistema cardiovascular, el aparato respiratorio y el digestivo, entre otros. El tratamiento de elección, mediante la inyección intramuscular de adrenalina, debe ser precoz. Por lo anterior, es vital estar preparados para reconocerla adecuadamente. El objetivo de la presente guía de actuación clínica es mejorar el conocimiento de los profesionales sanitarios sobre anafilaxia y, consecuentemente, optimizar el tratamiento y manejo a largo plazo de esta entidad. La guía está adaptada a las peculiaridades de América Latina, especialmente en los aspectos relativos al tratamiento. Se destaca la necesidad de introducir los autoinyectores de adrenalina en los países que no dispongan de ellos.


Asunto(s)
Anafilaxia , Guías de Práctica Clínica como Asunto , Agonistas Adrenérgicos/administración & dosificación , Agonistas Adrenérgicos/uso terapéutico , Adulto , Algoritmos , Anafilaxia/diagnóstico , Anafilaxia/epidemiología , Anafilaxia/etiología , Anafilaxia/terapia , Reanimación Cardiopulmonar , Niño , Terapia Combinada , Manejo de la Enfermedad , Vías de Administración de Medicamentos , Epinefrina/administración & dosificación , Epinefrina/uso terapéutico , Glucagón/administración & dosificación , Glucagón/uso terapéutico , Humanos , Pruebas Inmunológicas , Educación del Paciente como Asunto , Autoadministración , Vasoconstrictores/administración & dosificación , Vasoconstrictores/uso terapéutico
16.
Cell Stem Cell ; 25(3): 407-418.e6, 2019 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-31303548

RESUMEN

Hematopoietic stem cells (HSCs) residing in the bone marrow (BM) accumulate during aging but are functionally impaired. However, the role of HSC-intrinsic and -extrinsic aging mechanisms remains debated. Megakaryocytes promote quiescence of neighboring HSCs. Nonetheless, whether megakaryocyte-HSC interactions change during pathological/natural aging is unclear. Premature aging in Hutchinson-Gilford progeria syndrome recapitulates physiological aging features, but whether these arise from altered stem or niche cells is unknown. Here, we show that the BM microenvironment promotes myelopoiesis in premature/physiological aging. During physiological aging, HSC-supporting niches decrease near bone but expand further from bone. Increased BM noradrenergic innervation promotes ß2-adrenergic-receptor(AR)-interleukin-6-dependent megakaryopoiesis. Reduced ß3-AR-Nos1 activity correlates with decreased endosteal niches and megakaryocyte apposition to sinusoids. However, chronic treatment of progeroid mice with ß3-AR agonist decreases premature myeloid and HSC expansion and restores the proximal association of HSCs to megakaryocytes. Therefore, normal/premature aging of BM niches promotes myeloid expansion and can be improved by targeting the microenvironment.


Asunto(s)
Envejecimiento Prematuro/patología , Envejecimiento/fisiología , Médula Ósea/fisiología , Células Madre Hematopoyéticas/fisiología , Megacariocitos/fisiología , Células Mieloides/fisiología , Progeria/patología , Agonistas Adrenérgicos/administración & dosificación , Envejecimiento/metabolismo , Envejecimiento Prematuro/metabolismo , Animales , Diferenciación Celular , Encapsulación Celular , Proliferación Celular , Modelos Animales de Enfermedad , Humanos , Interleucina-6/metabolismo , Ratones , Óxido Nítrico Sintasa de Tipo I/metabolismo , Progeria/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Transducción de Señal , Nicho de Células Madre
17.
J Cardiovasc Electrophysiol ; 30(6): 896-901, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30907461

RESUMEN

INTRODUCTION: The epinephrine challenge has been proposed to improve the diagnosis of congenital long QT syndrome (LQTS). The aim of the study was to evaluate the diagnostic reliability of the epinephrine provocative test for LQTS diagnosis, taking into consideration intra- and interobserver variability in the interpretation of the test. METHODS AND RESULTS: A retrospective analysis of 79 consecutive epinephrine provocative tests was conducted. Epinephrine was administered following a standardized protocol at two doses: 0.05 and 0.10 µg kg-1 min-1 . Electrocardiograms were blindly read twice by three different operators at ≥1-week interval. QT and RR intervals were collected at rest and at each dose, as well as final operator interpretation of the test. There was a high interobserver reproducibility of corrected QT measurements with an intraclass correlation (ICC) of 0.74 (95% confidence interval, 0.66-0.80) but a low interobserver reproducibility on the final interpretation with a κ of 0.31. Intraobserver reproducibility of corrected QT was very good (ICC 0.93; 0.91-0.95), but still resulted in an only moderate intraobserver reproducibility in the final diagnosis (κ of 0.47). Perceived certainty of at least 1 reading by 2 operators (N = 62 tests) increased interobserver reproducibility compared with baseline (κ = 0.43). CONCLUSION: Inter- and intraobserver agreement in the interpretation of the epinephrine provocation test for LQTS is poor to modest. Complexity in interpretation varies from one case to the next. The low reliability of this test encourages a reconsideration of its importance in the clinical management of patients with suspected LQTS.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Electrocardiografía , Epinefrina/administración & dosificación , Frecuencia Cardíaca , Síndrome de QT Prolongado/diagnóstico , Potenciales de Acción , Adolescente , Adulto , Anciano , Niño , Femenino , Humanos , Síndrome de QT Prolongado/genética , Síndrome de QT Prolongado/fisiopatología , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Estudios Retrospectivos , Factores de Tiempo , Adulto Joven
18.
BMC Musculoskelet Disord ; 20(1): 61, 2019 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-30736773

RESUMEN

BACKGROUND: Although intraoperative periarticular multi-drug injection has been used for postoperative pain control after total knee arthroplasty (TKA), the injection has the inherent shortcoming of limited acting time. This randomized controlled trial was performed to assess whether adding percutaneous periarticular multi-drug injection at the day following TKA would improve the postoperative pain relief. METHODS: A total of 43 participants were randomly assigned to receive additional periarticular injection at 08:30, postoperative day 1 or no additional injection. The multi-drug solution including 40 mg of methylprednisolone, 150 mg of ropivacaine, and 0.1 mg of epinephrine was infiltrated into the muscle belly of the vastus medialis. In both groups, patients were treated with intraoperative periarticular multi-drug injection and postoperative intravenous and oral nonsteroidal anti-inflammatory drugs. We did not use any narcotic pain medications postoperatively. The primary outcome was the patients' global assessment of postoperative pain at rest measured using a visual analog scale (VAS) and quantified as the area under the curve (AUC) of serial assessments until 20:00, postoperative day 5. RESULTS: The mean AUC for the postoperative pain VAS at rest was 1616 ± 1191 in patients received the additional periarticular injection versus 2808 ± 1494 in those received no injection (mean difference, - 1192; 95% confidence interval, - 2043 to - 340; p = 0.007). No wound complication or surgical site infection was observed in either groups. CONCLUSIONS: Adding percutaneous periarticular multi-drug injection at the day following TKA may provide better postoperative pain relief. Further studies are needed to confirm the safety of the percutaneous injection. TRIAL REGISTRATION: University Hospital Medical Information Network UMIN000029003 . Registered 5 September 2017.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Anestésicos Locales/administración & dosificación , Artroplastia de Reemplazo de Rodilla/efectos adversos , Epinefrina/administración & dosificación , Glucocorticoides/administración & dosificación , Metilprednisolona/administración & dosificación , Manejo del Dolor/métodos , Dolor Postoperatorio/prevención & control , Ropivacaína/administración & dosificación , Agonistas Adrenérgicos/efectos adversos , Anciano , Anciano de 80 o más Años , Anestésicos Locales/efectos adversos , Antiinflamatorios no Esteroideos/administración & dosificación , Combinación de Medicamentos , Epinefrina/efectos adversos , Femenino , Glucocorticoides/efectos adversos , Humanos , Inyecciones , Japón , Masculino , Metilprednisolona/efectos adversos , Persona de Mediana Edad , Manejo del Dolor/efectos adversos , Dimensión del Dolor , Dolor Postoperatorio/diagnóstico , Dolor Postoperatorio/etiología , Estudios Prospectivos , Ropivacaína/efectos adversos , Factores de Tiempo , Resultado del Tratamiento
19.
Life Sci ; 221: 362-376, 2019 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-30797820

RESUMEN

The human eye being a complex and a very sensitive organ makes the drug delivery task challenging. An increase in the intra-ocular pressure at the aqueous humour leads to glaucoma which is not only indecipherable but can also be the reason of blindness for many. The presently available marketed formulations using anti-glaucoma drugs have issues of either difficulty in crossing the blood- retinal barrier or lower systemic bioavailability. Hence, the drugs having lower therapeutic index would need to be administered frequently, which eventually lead to deposition of concentrated solutions at ocular site, producing toxic effects and cellular damage to the eye. To overcome these drawbacks the novel drug delivery systems like In-situ gels, liposomes, niosomes, hydrogel, dendrimers, nanoparticles, solid lipid nanoparticles, Microneedles or ocular inserts play an important role to enhance the therapeutic efficacy of the anti-glaucomic drugs. The present review briefs the current treatments in terms of drugs used and in detail the impact of utilizing the above mentioned novel drug delivery systems in the treatment of glaucoma.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Glaucoma/tratamiento farmacológico , Glaucoma/terapia , Agonistas Adrenérgicos/administración & dosificación , Antagonistas Adrenérgicos beta/administración & dosificación , Disponibilidad Biológica , Inhibidores de Anhidrasa Carbónica/administración & dosificación , Dendrímeros , Composición de Medicamentos , Ojo , Humanos , Presión Intraocular , Liposomas , Prostaglandinas Sintéticas/administración & dosificación
20.
Ginekol Pol ; 89(8): 453-58, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30215466

RESUMEN

BACKGROUND: Hemodynamic change during spinal anaesthesia for cesarean section is prevalent. OBJECTIVE: Comparing the prophylactic effects of ephedrine, ondansetron and ringer on hemodynamic changes in patients undergoing cesarean section with spinal anaesthesia. MATERIAL AND METHODS: This randomized clinical trial was carried out on pregnant women undergoing elective cesarean sec-tion referred to teaching hospitals of Mashhad, Iran. Patients allocated to three groups of intravenous ondansetron (O) (4 mg, 5 min),intramuscular ephedrine (E) (25 mg, 25 min) and ringer (R) (500 ml, 20 min) prior to spinal anaesthesia. Anaesthesia inducted with 10-15 mg of bupivacaine. Vital signs were recorded every 3 minutes for 18 minutes including systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse rate (PR), pulse oximetry (SpO2). RESULTS: Ninety patients with a mean age of 29.4 ± 5.4 years were studied in three groups of O (n = 30), E (n = 30), R (n = 30). Results showed a statistically significant difference in the incidence rate of hypotension 12 minutes after spinal anaesthesia in the three groups, but no statistically significant difference was found in the rest of minutes among the three groups. Dur-ing follow-up minutes, bradycardia was observed in only one patient (1.1%) of Group O and no cases of this sign were observed in other minutes and other groups. CONCLUSION: Intramuscular administration of ephedrine 25 minutes prior to the spinal anaesthesia leads to better prevention of systolic blood pressure changes compared with intravenous ondansetron and ringer, while administration of ondansetron and ringer had the same effects on reducing hemodynamic changes.


Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Anestesia Obstétrica/métodos , Anestesia Raquidea/métodos , Cesárea/métodos , Epinefrina/administración & dosificación , Hemodinámica/efectos de los fármacos , Ondansetrón/administración & dosificación , Solución de Ringer/administración & dosificación , Antagonistas del Receptor de Serotonina 5-HT3/administración & dosificación , Agonistas Adrenérgicos/efectos adversos , Adulto , Anestesia Obstétrica/efectos adversos , Anestesia Raquidea/efectos adversos , Presión Arterial/efectos de los fármacos , Cesárea/efectos adversos , Epinefrina/efectos adversos , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Irán , Ondansetrón/efectos adversos , Embarazo , Solución de Ringer/efectos adversos , Antagonistas del Receptor de Serotonina 5-HT3/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...